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ABSTRACT 
 
Background: Patients with juvenile idiopathic arthritis (JIA) often present with signs 
and symptoms suggestive of serious bacterial infection (SBI).  However, it is a 
challenge to differentiate infectious from non-infectious presentation in routine 
clinical care. Procalcitonin (PCT) is a serum biomarker that is elevated in the setting 
of SBI, but whether it can reliably differentiate infection from disease flare in patients 
with JIA is unknown.1 We conducted a prospective cohort study to test the hypothesis 
that PCT levels will differ between active JIA, quiescent JIA, and bacteremic patients 
and healthy controls. 
 
Methods: From 10/16-4/18, consecutive children 6 months - 18 years of age with a) 
active untreated JIA (=>4 inflamed joints) b) quiescent JIA and c) healthy elective 
pre-surgical candidates were recruited from clinics at a musculoskeletal specialty 
hospital. JIA was defined according to ILAR criteria. Patients with active JIA despite 
treatment were excluded, to avoid confounding by treatment. Clinical data and serum 
samples from children with active and quiescent JIA meeting the same criteria were 
included from a prior study. Consecutive bacteremic patients were identified from an 
associated pediatric intensive care unit over the same period. No matching was 
performed. PCT as well as other common measures of inflammation were measured. 
Descriptive statistics and univariate logistic analyses were performed as appropriate 
using SAS version 9.4. The study was IRB approved.  
 
Results: Bacteremic patients were younger than patients in the other three groups 
(median age 2.1 vs. 14.0 years) and had a variety of infections. ESR, CRP, and PCT 
were all elevated in bacteremic patients in comparison to the other groups. ESR and 
CRP both had wide ranges that overlapped between groups; however, the PCT 
concentration exceeded 0.15ug/mL in 0 out of 27 patients with active JIA and 1 out of 
32 patients with quiescent JIA, while it was <= 0.15ug/mL in only 1 bacteremic 
patient. PCT did not differ between patients with active and quiescent JIA.  
 
Conclusions: Our study indicates that serum ESR, CRP, and PCT levels are all 
biomarkers that can be used to distinguish SBI vs. active JIA at presentation. 
However, PCT is the most accurate, with the least overlap between patients with 
infection and non-infectious inflammatory arthritis. This finding can help clinicians 
direct therapy. However, PCT is not a useful biomarker to assess disease activity in 
JIA. Further studies are needed to assess whether measurement of serum PCT is useful 
in differentiating JIA flares from less severe infections.
                                                          
1 Karen Milcent et al., “Use of Procalcitonin Assays to Predict Serious Bacterial Infection in Young 
Febrile Infants,” JAMA Pediatrics 170, no. 1 (January 1, 2016): 62–69, 
doi:10.1001/jamapediatrics.2015.3210; Mohammad Reza Shokrollahi et al., “Diagnostic Value of CRP, 
Procalcitonin, and Ferritin Levels in Cerebrospinal Fluid of Children with Meningitis,” Central Nervous 
System Agents in Medicinal Chemistry, March 1, 2016; Ruimei Hu, Yansheng Gong, and Yuzhen Wang, 
“Relationship of Serum Procalcitonin Levels to Severity and Prognosis in Pediatric Bacterial Meningitis,” 
Clinical Pediatrics 54, no. 12 (October 2015): 1141–44, doi:10.1177/0009922815569203; Abdel Hakeem 
Abdel Mohsen and Bothina Ahmed Kamel, “Predictive Values for Procalcitonin in the Diagnosis of 
Neonatal Sepsis,” Electronic Physician 7, no. 4 (August 2015): 1190–95, doi:10.14661/2015.1190-1195. 
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BIOGRAPHICAL SKETCH 
 
Since I was in high school, I have wanted to go to medical school and become a 
doctor. I slowly pursued that dream by completing all the pre-medical requirements at 
Barnard College, taking the MCAT, and applying to medical school. Once I was in 
medical school at Albert Einstein College of Medicine, I first became aware of my 
interest in rheumatology during the first two years of classroom courses, and then for 
pediatrics, during the clinical rotations. I decided to pursue a career in pediatric 
rheumatology, and I have been extremely satisfied with my choice. As I have 
progressed through the various stages of my medical education, my vision for my 
career has become more clear.  
During medical school and residency at NYU Langone Medical Center/Bellevue 
Hospital Center, I was fortunate to have the opportunity to refine my ideas of what I 
was interested in. I always knew that I enjoyed clinical work and taking care of 
patients. But during medical school, I took a year to do research, and I worked with 
multiple researchers in the Division of General Pediatrics at Montefiore. I contributed 
to many projects, ranging from care of neonates to use of Hydroxyurea in sickle cell 
disease. I was engaged in multiple aspects of the research, including qualitative 
interviews and transcript review, organization of data, statistical analysis, and writing 
manuscripts. I found this work extremely rewarding, and it appealed to me in two 
ways. First, I enjoyed the analysis, problem solving, and brainstorming and felt that it 
utilized a very different part of my brain from the clinical care to which I had become 
accustomed. Second, it was rewarding, and I enjoyed the idea that I could make a 
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difference not only to my patients, but that I could effect changes in management for 
many more providers and patients in the future based on my research work. 
Throughout my fellowship at Weill Cornell Medicine/Hospital for Special Surgery, I 
have engaged in clinical and translational research. I have conducted a prospective 
cohort study to evaluate (1) procalcitonin as a biomarker for differentiation of 
infection and disease activity in children with juvenile idiopathic arthritis, and (2) the 
value of Patient Reported Outcome Measurement Information System Computer 
Adaptive Tests (PROMIS CATs) in children with JIA. I have presented some of my 
work at national conferences, and have thoroughly enjoyed these experiences. I also 
won the Charles L. Christian Award for Excellence in Musculoskeletal Research at the 
completion of my fellowsip. In addition, I am currently enrolled in the Weill Cornell 
Clinical and Translational Science Center Master’s Program for Clinical and 
Translational Investigation. This exciting opportunity has allowed me to continue to 
build my skills and knowledge about research.   
At this point, I feel lucky to have a solid sense of what I want for my career, as well as 
the resources and mentors to help me get there. I enjoy working with patients, and will 
continue to do that. I also look forward to the opportunity to engage in research for a 
significant part of my effort, in order to help further evidence-based medicine and 
treatment in pediatric rheumatology. I look forward to continuing to pursue these 
goals, with the foundation that I have developed through the Weill Cornell Clinical 
and Translational Science Center Master’s Program for Clinical and Translational 
Investigation.   
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BACKGROUND 
 
 
Juvenile Idiopathic Arthritis (JIA) is a chronic autoimmune disease that affects 
approximately 300,000 children in the United States.1 Monitoring of disease activity 
relies upon history, physical examination, and laboratory data. However, because of 
overlapping features between JIA and various complications, diagnosis and 
management can be difficult, both at disease onset and during disease flares. Many 
studies have been done with the goal of finding new biomarkers for monitoring of 
disease activity and complications in JIA, based on basic science research and clinical 
studies in adult patients.2,3,4 However, few studies have yielded positive results, and 
the key diagnostic challenges persist.  
 
One specific situation that requires better objective data is the diagnosis of infection 
versus flare in JIA. This distinction is often hampered by diagnostic uncertainty, 
patient age, and administration of chronic immunosuppressive therapy. The evaluation 
and management for infection carries significant morbidity and often delays the 
initiation of appropriate anti-rheumatic treatment. Therefore, distinguishing between 
these two entities is of great clinical importance. However, no clear biomarkers have 
been found to accomplish this goal.  
 
Procalcitonin (PCT) is a molecule that is consistently elevated in bacterial infection.5,6  
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PCT is typically secreted by C cells of the thyroid, and then cleaved to calcitonin.7 
During stress, PCT secretion is elevated by multiple mechanisms: (1) excessive 
production, (2) decreased cleavage to calcitonin, and (3) extra-thyroidal transcription 
and synthesis. There is evidence indicating that this occurs exclusively in bacterial 
infections.8,9 
 
Few studies have examined this biomarker in children with chronic inflammatory 
disease. The utility of PCT has been evaluated in Kawasaki disease and Henoch 
Schonlein purpura.10,11[ The performance of PCT to distinguish increased disease 
activity from bacterial infection is unknown in children with JIA.  Therefore, this 
prospective cohort study was designed to test that the hypotheses that (1) PCT can 
distinguish infection from active disease in JIA, and (2) PCT will differentiate 
between active and quiescent disease in children with JIA.  
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METHODS 
 
Patient Population 
 
Between 10/2016 and 5/2018, four groups of consecutive children aged 1 to 18 years 
were recruited from a single academic center during a standard of care visit: 
a) Active JIA 
b) Quiescent JIA  
c) Children without rheumatic disease undergoing elective surgery 
d) Children with bacteremia admitted to the pediatric intensive care unit 
 
JIA was defined according to ILAR criteria.12 Active JIA was defined as incident 
cases untreated with anything besides NSAIDs, and ≥4 inflamed joints; quiescent JIA 
was defined as prevalent treated cases, with <4 inflamed joints, and stable treatment 
for ≥1 month. Exclusion criteria included: (1) non-English speaking patients/parents 
because some of the disease assessment tools utilized in this study are only validated 
in English; (2) patients with oligoarticular type JIA; (3) patients with systemic onset 
JIA; (4) patients with active JIA despite treatment to minimize  confounding by 
treatment; (5) patients with other rheumatologic diagnoses; (6) patients with primary  
3 
renal disease; (7) patients taking stimulant medications because these drugs can affect 
PCT levels13,14; and (8) patients with current infection. Inclusion and exclusion criteria 
for surgical controls and bacteremic patients can be found in the supplemental criteria. 
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Data Collection 
 
The following information was collected for each patient: JADAS-71 scores [score 0-
101, including swollen joint count, physician global health assessment, patient global 
health assessment, and modified erythrocyte sedimentation rate (ESR)]; Childhood 
Health Assessment Questionnaire (CHAQ); relevant laboratory data [complete blood 
count (CBC), ESR, C-reactive protein (CRP), and PCT]. All labs were processed at a 
single standard study laboratory. This study was approved by the Hospital for Special 
Surgery and Weill Cornell Medicine IRBs.  
 
Statistical Analysis 
 
PCT and ESR, CRP, and hemoglobin were compared between groups. Continuous 
variables were compared using ANOVA or Wilcoxon rank-sum test, and categorical 
variables were compared using Fisher’s exact test. 
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RESULTS 
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Patient characteristics of all four groups are summarized in Table 1. Most groups had a 
median age of 13-14 years, although bacteremic patients were younger than the other 
groups (median age 2.1 vs. 14.0 years). Most groups were predominantly White or 
Caucasian, except for the bacteremic patients, who were more racially diverse.  
 
JIA characteristics of our patient groups are further characterized in Table 2. Both the 
active and quiescent groups had a mix of JIA subtypes. Because active JIA were 
defined as incident, disease duration was significantly shorter in this group than in the 
children with quiescent, prevalent JIA. Overall, approximately 47% of our patients 
were positive for ANA, while fewer patients were positive for other autoantibodies 
and disease markers of known significance. 
 
Laboratory values for all study participants are summarized in Table 3. ESR, CRP, 
and PCT were all elevated in bacteremic patients in comparison to the other groups. 
ESR and CRP both had wide ranges that overlapped between groups (Figure 1 and 2); 
however, the PCT concentration exceeded 0.15ug/mL, the standard cutoff for 
suspicion for infection in 0 out of 27 patients with active JIA and 1 out of 32 patients 
with quiescent JIA, while PCT concentrations exceeded this level 16 out of 17 
bacteremic patients (Figure 3). PCT did not differ between patients with active and  
quiescent JIA. Based on this data, sensitivity and specificity for PCT and infection 
were 94.1% and 98.3% (Table 4), and positive predictive value and negative 
predictive value were 94.1% and 98.3%. 
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Table 1. Patient characteristics 
 
 
 
 Active 
Untreated  
JIA (n = 27) 
Quiescent JIA 
(n = 32) 
Healthy 
Controls  
(n = 16) 
Bacteremic 
Patients  
(n = 17) 
Age, years  
(median, IQR) 
13.0 
[7.0, 16.0] 
14.0  
[10.8, 15.4] 
14.4  
[13.9, 15.5] 
2.1  
[0.8, 8.8] 
Sex     
   Male 11 (40.7%) 5 (15.6%) 6 (37.5%) 10 (58.8%) 
Race     
   Caucasian/White 20 (74.1%) 30 (93.8%) 12 (75.0%) 5 (29.4%) 
   AA/Black 3 (11.1%) 0 (0.0%) 3 (18.8%) 4 (23.5%) 
   Asian 3 (11.1%) 1 (3.1%) 0 (0.0%) 3 (17.7%) 
   Other 1 (3.7%) 1 (3.1%) 1 (6.3%) 5 (29.4%) 
Ethnicity     
   Hispanic 0 (0%) 4 (12.5%) 1 (6.3%) 1 (5.9%) 
 
 
 
7 
 
 
 
 
 
Table 2. JIA disease characteristics 
 
 
 Active and 
quiescent JIA 
(n=59) 
Active JIA 
(n=27) 
Quiescent JIA 
(n=32) 
JIA category    
   Polyarticular 14 (23.7%) 6 (22.2%) 8 (25.0%) 
   Psoriatic 12 (20.3%) 6 (22.2%) 6 (18.8%) 
   Spondyloarthropathy 33 (56.0%) 15 (55.6%) 18 (56.2%) 
Disease duration (mean) 6-12 months 3-6 months 2-3 years 
ANA+ 28 (47.4%) 10 (37.0%) 17 (53.1%) 
B27+ 11 (18.6%) 4 (14.8%) 16 (50.0%) 
RF+ 4 (6.8%) 2 (7.4%) 13 (40.6%) 
CCP+ 8 (13.5%) 4 (14.8%) 11 (34.4%) 
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Table 3. Laboratory values 
 
 
 Active 
Untreated  
JIA (n = 27) 
Quiescent JIA 
(n = 32) 
Healthy 
Controls  
(n = 16) 
Bacteremic 
Patients  
(n = 17) 
p-
value 
WBC 7.0 [5.6, 8.2] 7.4 [6.2, 8.2] 6.9 [5.3, 8.4] 7.7 [4.9, 13.0] 0.72 
Hemoglobin 12.6  
[11.9, 13.3] 
13.1  
[12.4, 13.9] 
14.0  
[12.5, 14.3] 
9.9  
[9.3, 11.1] 
<0.001 
Platelets 288 [248, 353] 273 [218, 308] 293 [243, 316] 200 [148, 259] 0.004 
ESR 10 [6, 20] 6 [2, 10] 8 [5, 10] 50 [27, 67] <0.001 
CRP 1.40  
[0.12, 5.20] 
0.18  
[0.06, 0.57] 
0.42  
[0.14, 1.56] 
10.45 
[3.80, 17.40] 
<0.001 
Procalcitonin 0 [0, 0] 0 [0, 0] 0 [0, 0] 6.68  
[1.93, 21.58] 
<0.001 
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Figure 1. ESR in JIA vs. Infection 
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Figure 2. CRP in JIA vs. Infection 
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Figure 3. PCT in JIA vs. Infection 
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Table 4. Sensitivity, Specificity, Positive Predictive Value,  
and Negative Predictive Value for PCT 
 
 Point Estimate Confidence Interval 
Sensitivity 94.1% 71.3% - 99.9% 
Specificity 98.3% 90.9% - 99.9% 
Positive Predictive Value 94.1% 69.5% - 99.1% 
Negative Predictive Value 98.3% 89.7% - 99.7% 
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DISCUSSION 
 
To our knowledge, this is the first study to examine PCT specifically in children with 
JIA, for its utility in differentiating infection and non-infectious inflammatory disease 
activity. Korczowski et al evaluated procalcitonin, CRP, and ESR in 28 children with 
autoimmune disease, 9 of whom had juvenile arthritis.15 They found that while ESR 
and CRP are sometimes elevated in children with autoimmune disease, PCT remains 
low in this population. This study concluded that PCT may be useful for 
differentiation of infection and inflammatory disease activity; however, findings were 
not disease specific. 
 
Recently, multiple studies have been done evaluating PCT and additional biomarkers 
for differentiation of infection and inflammatory disease activity in systemic 
autoimmune diseases, especially systemic lupus erythematosus.16,17 These studies have 
repeatedly shown that PCT, in conjunction with other biomarkers, can reliably 
differentiate infection from an inflammatory disease flare. A meta-analysis performed 
by Serio et al in 2014 confirmed this finding.18   
 
Here, we evaluated PCT as a marker for infection vs. non-infectious inflammation in 
children with JIA specifically. Our study indicates that serum ESR, CRP, and PCT  
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levels are all biomarkers that can be used to distinguish serious bacterial infection 
from active JIA at presentation. However, PCT is the most accurate, with the least 
overlap between patients with infection and non-infectious inflammatory arthritis, and 
a high sensitivity and specificity. This finding can help clinicians direct therapy more 
accurately and swiftly at disease onset. However, PCT is not a useful biomarker to 
assess disease activity in JIA, as PCT levels did not differ between patients with active 
incident JIA and quiescent prevalent JIA. 
 
Some strengths of this study include recruitment of multiple groups of patients for 
comparison, including children with active incident JIA, quiescent prevalent JIA, 
healthy pre-surgical candidates, and children with serious bacterial infection. Some 
limitations of our study are that this was performed at a single center with a limited 
sociodemographic population. It is important to note that the age and race differed 
between the group of patients with infection and the other three groups; however, 
there is currently no data to support that PCT differs by age or race.  
 
This study is the first step towards establishing a biomarker panel that can differentiate 
infection and inflammatory disease activity in children with JIA. We have shown that 
in this population of patients, PCT remains reliably low, even when disease is active 
and other more commonly used inflammatory markers are elevated. Further studies 
are needed to assess additional biomarkers in conjunction with PCT for distinction of  
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infection and disease flare, throughout disease course. Further evaluation and 
measurement of serum PCT for differentiating JIA flares from less severe infections is 
also required. 
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